SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 5/20/02 Martek Biosciences Corp 8-K:5 5/20/02 1:17K Bowne - DC/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 18K
e8-k |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2002
Martek Biosciences Corporation
(Exact name of registrant as specified in its
charter)
Delaware | 000-22354 | 52-1399362 | ||
(State or other jurisdiction of | (Commission File | (I.R.S. Employer | ||
incorporation or organization) | Number) | Identification No.) |
6480 Dobbin Road Columbia, Maryland | 21045 | |||
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (410) 740-0081
MARTEK BIOSCIENCES CORPORATION
Item 5. | Other Events |
On May 20, 2002, a Registration Statement on Form S-3 (SEC File No. 333-87934) relating to the resale of up to 1,776,306 shares of common stock of Martek Biosciences Corporation (“Martek” or the “Registrant”) was declared effective by the Securities and Exchange Commission (“SEC”). Under the Registration Statement, former stockholders and creditors of OmegaTech, Inc., which was acquired by Martek on April 25, 2002, may offer for sale initially up to 1,265,213 shares of Martek common stock from time to time on the Nasdaq national market or through block sales or other methods at their discretion. The remainder of the shares may be offered for sale following the expiration of various lock-up or escrow agreements.
In connection with the effectiveness of the Registration Statement, certain individuals listed in the table below each entered into a Selling Plan under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, with Adams, Harkness & Hill, Inc. (“AH&H”). Under the Selling Plans, AH&H will undertake to sell for each of these individuals the number of shares listed in the table below. AH&H will have the discretion to sell the number of shares covered by the Selling Plans at or above a set minimum price for a period up to June 7, 2002 and shall sell the remaining shares at the best price that secures timely liquidity after June 7, 2002.
Name | Martek Title | Number of Shares | ||||||||
Covered by Selling | ||||||||||
Plan | ||||||||||
Mark Braman |
Executive Vice President | 24,937 | ||||||||
James Flatt |
Senior Vice President – | 7,866 | ||||||||
Research and Development | ||||||||||
Robert Di Scipio |
Vice President, Associate | 15,500 | ||||||||
General Counsel and | ||||||||||
Assistant Secretary | ||||||||||
Michael Klacik |
Director of | 8,440 | ||||||||
Business Development | ||||||||||
William Barclay |
Director of Discovery | 6,497 | ||||||||
Item 7. | Financial Statements, Pro Forma Financial Information and Exhibits |
None.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MARTEK BIOSCIENCES CORPORATION | ||||||
Date: | May 20, 2002 | By: | /s/ George P. Barker | |||
George P. Barker | ||||||
Senior Vice President, General | ||||||
Counsel and Secretary |
-3-
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
6/7/02 | ||||
Filed on / For Period End: | 5/20/02 | S-3/A | ||
4/25/02 | 8-K, 8-K/A | |||
List all Filings |